AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01112722 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Apitox, purified honeybee toxin, lyophilized in saline
Description: intradermal injections of 0.1mg apitox in 0.1ml WFI over 12 weeks treatment period, injections twice weekly range from 1 to 20 injections
Study NCT01112722 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: histamine
Description: imitates pain and erythema of honeybee venom
Study NCT03010657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Subjects will be asked to consume certain foods during chemotherapy treatment.
Study NCT03498560 — intervention group
Intervention type: DEVICE
Intervention: PSG
Description: PSG data to be collected on the night before surgery to establish level of preexisting sleep disturbance.
Study NCT02235558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Super-selective intra-arterial administration of 10mg verapamil in 20cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot, immediately following successful intra-arterial thrombolysis. Half-life is 2.8-7.4 hrs.
Study NCT04342936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: A humanized monoclonal immunoglobulin
Study NCT04342936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's choice of Chemotherapy
Description: Participants will receive one of the following chemotherapies for up to 6 cycles:~Gemox: Gemcitabine and Oxaliplatin； IGEV: Ifosfamide, Gemcitabine, Vinorelbine, and Prednisolone； DHAP: Dexamethasone, high-dose Cytarabine (Ara-C) and Cisplatin.
Study NCT01525628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: CYP3A probe drug
Study NCT01525628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: HCV protease inhibitor
Study NCT01525628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir
Description: nucleoside analogue
Study NCT01525628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine
Description: CYP1A2 probe drug
Study NCT01525628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolbutamide
Description: CYP2C9 probe drug
Study NCT01525628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon
Description: HCV treatment
Study NCT01525628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: HCV polymerase inhibitor
Study NCT01525628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: HCV treatment
Study NCT01750827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB659032
Description: single dose
Study NCT02803827 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rapid diagnostics
Description: Participants will have enteric specimens obtained using a flocked rectal swab, which will be transported in 2 mL Cary Blair medium. These will be tested using the BioMerieux BioFire FilmArray GI panel.
Study NCT02803827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid diagnostics
Description: Participants will have enteric specimens obtained using a flocked rectal swab, which will be transported in 2 mL Cary Blair medium. These will be tested using the BioMerieux BioFire FilmArray GI panel.
Study NCT02803827 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Probiotic
Description: The probiotic given will be Lactobacillus reuteri DSM 17938, 5x10e8 cfu/mL x 60 days, suspended in vegetable oil.
Study NCT02803827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The probiotic given will be Lactobacillus reuteri DSM 17938, 5x10e8 cfu/mL x 60 days, suspended in vegetable oil.
Study NCT03095534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-Step Workout for Life
Description: a 10-week moderate exercise program
Study NCT01673048 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3-Nail-ESIN in femoral shaft fractures
Study NCT03636503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells. Stem cells (young cells in the bone marrow that will develop into the various types of cells) do not have the CD20 antigen. This allows healthy B-cells to regenerate after treatmen
Study NCT06760247 — intervention group
Intervention type: PROCEDURE
Intervention: intubated general anesthesia with propofol IV, rocuronium IV ,sevoflurane and N2O gas
Description: endotracheal intubation by using direct laryngoscopy
Study NCT03636503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Utomilumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug
Study NCT03636503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug
Study NCT02803827 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be the vegetable oil vehicle and look identical to the probiotic.
Study NCT03636503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF04518600
Description: In the presence of tumor-associated antigens (TAAs), this may promote a T-cell-mediated immune response against TAA-expressing tumor cells. OX40
Study NCT02803827 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: The placebo will be the vegetable oil vehicle and look identical to the probiotic.
Study NCT03715751 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ASV
Description: Adaptive Support Ventilation
Study NCT03715751 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lung Protective Ventilation
Description: Targeted tidal volume of 6cc/Kg, Positive Inspiratory Pressure titrated per ARDS guidelines.
Study NCT00989716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal glyceryl trinitrate patch
Description: 5mg per day
Study NCT00989716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-stroke antihypertensives
Description: Continue or stop pre-stroke anti-hypertensives
Study NCT02117141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-ER 20 mg capsule (fasted)
Description: Single oral dose HC-ER 20 mg capsule after overnight fast (fasted)
Study NCT02117141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-ER 20 mg capsule (fed)
Description: Single oral dose HC-ER 20 mg capsule after high fat meal (fed)
Study NCT04094506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1948
Description: Intravenous
Study NCT02733211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD- Logic Closed Loop System
Description: Closed Loop System
Study NCT02733211 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sensor augmented pump therapy
Description: Sensor augmented pump therapy
Study NCT03045198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Study NCT02607826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Starvation
Description: Short-term starvation for a timeframe beginning 24h prior to chemotherapy administration, lasting until 6h after administration
Study NCT01232660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 400mg once daily orally
Study NCT01232660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 400mg once daily orally
Study NCT01600313 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: rice bran oil
Description: Treatment group received the low - calorie diet with(30g/day) rice bran oil
Study NCT01459380 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT01459380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02096159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole
Study NCT01459380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01459380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV
Study NCT01459380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT04785053 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial alternating current stimulation (tACS)
Description: The tACS intervention (gamma stimulation, theta stimulation and active sham condition) will be administered to the participants over three visits that will be completed within one of the working days (Mon-Fri) at approximately the same time of day for all participants. Participants will be randomized and blinded to the tACS treatment.
Study NCT02096159 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01646320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
Study NCT01646320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with Dapagliflozin
Description: Tablets, Oral, 0 mg, Once daily, Up to 52 weeks
Study NCT01646320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 5 mg, Once daily, Up to 52 weeks
Study NCT01646320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin immediate release (IR)
Description: Tablets, Oral, ≥ 1500 mg, Twice daily, Up to 52 weeks
Study NCT04086771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation
Description: Weekly phone-calls, personal messages, and American Cancer Society Pap test and mammography test reminder post card
Study NCT04086771 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Information only
Description: American Cancer Society breast and cervical cancer screening information and Pap test and mammography test reminder post card
Study NCT01457040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBI+CY+VP-16
Description: CR Cohort will receive conditioning regimen of TBI+CY+VP-16: TBI: 4.5Gy/d, -5d, -4d; CY: 60mg/kg/d, -3d, -2d; VP-16: 15mg/kg/d, -3d, -2d
Study NCT01457040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FA+TBI+CY+VP-16
Description: NR Cohort will receive conditioning regimen of FA+TBI+CY+VP-16: Flu: 35mg/m2/d: -10\~-6d; AraC: 1g/m2/d, -10d\~-6d; TBI: 4.5Gy/d, -5d,-4d; CY:60mg/kg/d, -3d, -2d; VP-16: 15mg/kg, -3d, -2d
Study NCT02460900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Study NCT02460900 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positively Smoke Free
Study NCT02460900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02460900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02460900 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Study NCT02460900 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Study NCT01158378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adherus Dural Sealant
Description: In situ polymerizing sealant
Study NCT01158378 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adherus Dural Sealant
Description: In situ polymerizing sealant
Study NCT02764775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Headpod
Description: Adaptive equipment to assist with active head movements
Study NCT04602494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: varenicline: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks
Study NCT04602494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks
Study NCT03325621 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRS-080#022-DP
Description: Biological/Vaccine: PRS-080#022-DP Hepcidin antagonism to mobilize iron and to treat anemia
Study NCT03325621 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PRS-080-Placebo#001
Description: Placebo Comparator
Study NCT02358460 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation delivered by SLE5000 ventilator
Description: In pressure-limited ventilation arm, ventilator settings as required to maintain appropriate oxygenation and carbon-dioxide elimination.~In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits.
Study NCT03260361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis, kinesitherapy, MEOPA
Description: classical intervention
Study NCT03260361 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual practice
Description: Usual practice with treatments and physio
Study NCT04207333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Arithmetic Test
Description: The researcher will call out a four-digit number and ask the participant to subtract either 7 or 13. Each minute, a new four-digit number will be called out and the participant must subtract the 7 or 13 from the number. The test will last approximately 5 minutes
Study NCT03074799 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Symptom -based Screening(Child Contacts)
Description: Aim 1: Determine the number of child contacts per adult index case of tuberculosis to assess quality of contact tracing.~Aim 2: Determine the percentage of child contacts initiated on IPT or antituberculous therapy (ATT) and compare between intervention (symptom-based, nurse-led initiation of IPT) vs control clinics (TST-based screening with referral to hospital, current standard of care).~Aim 3: Compare outcomes of children initiated on IPT between both groups including: completion of therapy, discontinuation due to side effects, lost to follow up, and adherence while on therapy.
Study NCT03074799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical based Decisions
Description: the child is symptomatic, they will be referred to the hospital for further evaluation of TB disease including both chest X-ray and testing of either sputum or swallowed sputum. If the child is asymptomatic, the TB nurse at the local clinic will initiate them on weight-appropriate dosing of IPT
Study NCT01867853 — intervention group
Intervention type: DEVICE
Intervention: PLR
Description: passive leg raising test was done before and at the end of SBT
Study NCT01062815 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral Nutrition
Description: Parenteral Nutrition infused over 20 hours cycled with dextrose solution over 4 hours compared to Parenteral Nutrition infused continuously over 24 hours.
Study NCT01062815 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Parenteral Nutrition
Description: Parenteral Nutrition infused over 20 hours cycled with dextrose solution over 4 hours compared to Parenteral Nutrition infused continuously over 24 hours.
Study NCT01506492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALM
Description: Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
Study NCT02293343 — intervention group
Intervention type: OTHER
Intervention: blood profile
Study NCT04534894 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fluorescence lifetime imaging microscopy
Description: collect 2mL of venous blood and use fluorescence lifetime imaging microscopy to exam NADH fluorescence characteristics of it
Study NCT04664660 — intervention group
Intervention type: OTHER
Intervention: Retrospective analysis of obstetrics outcomes
Description: Retrospective analysis of clinical records including general medical and gynecological history, pregnancy course, delivery mode and newborn conditions.
Study NCT03245476 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy focus on manual therapy and home-exercises
Description: corticoid injection + physiotherapy with a focus on manual therapy and home-exercises
Study NCT03245476 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy focus on education and supported home exercises
Description: corticosteroid injection + physiotherapy with focus on education and supported home exercises
Study NCT03851341 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Janumet XR tablet 100/1000 mg
Description: To administrate the Janumet XR tablet
Study NCT03851341 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: GLH1SM tablet 100/1000 mg
Description: To administrate the GLH1SM tablet
Study NCT02698423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cobas HPV DNA Test
Description: Women will receive a home-sent sample for HPV self-testing
Study NCT02698423 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Papanicolau test
Description: Women will be invited to come in for a physician-performed Pap test
Study NCT01742221 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HemaMax
Description: single subcutaneous 12 microgram dose of HemaMax
Study NCT01742221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single subcutaneous dose
Study NCT04304222 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 3D Printed Denture Framework
Description: The Denture Framework is 3D printed from the digital image obtained from the denture mold.
Study NCT01903434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally
Study NCT01081210 — intervention group
Intervention type: OTHER
Intervention: Ultrasound examination
Description: Screening with bedside ultrasound examination
Study NCT01471873 — intervention group
Intervention type: PROCEDURE
Intervention: Corneal Collagen Cross-linking (CXL)
Description: The same surgical procedure was applied to all CXLG patients that included:~Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well.
Study NCT01717612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thrombin
Description: Among the thrombin group, the injection site was also aimed at the bleeding varices or varices with red color signs or at the most prominent varices. The injected agents consisted of lyophilized human Thrombin in calcium chloride solution containing thrombin 500IU/ml). (Floseal, Baxter Healthcare Corporation, CA, Hayward, USA)
Study NCT01717612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Histoacryl
Description: The injection site was aimed at the bleeding varices or varices with red color signs or at the most prominent varices.
Study NCT00664274 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive remediation therapy
Description: 36 sessions of Computerized Cognitive Skills Training, 3 per week for 12 weeks.
Study NCT00664274 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: COMT Genotyping
Description: One time saliva sample is taken to genotype catechol-O-methyltransferase Val158/108Met alleles.
Study NCT02102061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multidisciplinary intervention
Description: a health- and quality of life-oriented program comprising exercise, nutrition advices, and philosophy meetings, without a focus on weight loss, following the philosophical principles from Health at Every Size.
Study NCT02239094 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lurasidone (Latuda)
Description: Antipsychotic medication approved for use with Bipolar disorder
Study NCT03216265 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Test product (Moisturising cream)
Description: Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).
Study NCT03216265 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Positive control (Commercial market place moisturising cream)
Description: Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).